Related Experiment Video
Updated: Jun 19, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Thromboembolic Risk in Sinus Rhythm: A New Paradigm in Light Chain Cardiac Amyloidosis
Giulia Marchionni1,2, Jacopo Costantino2, Federico Ballatore2
1University of Pavia, Pavia, Italy.
Insights
Cardiac amyloidosis significantly elevates thromboembolic risk beyond atrial fibrillation. Left atrial strain assessment is crucial for predicting clot events in these patients.
Area of Science:
- Cardiology
- Neurology
- Hematology
Background:
- Cardiac amyloidosis increases thromboembolic risk, often independent of atrial fibrillation.
- Patients with cardiac amyloidosis require comprehensive risk stratification for cerebrovascular events.
Abstract:
Thromboembolic risk is increased in cardiac amyloidosis, and this goes beyond the occurrence of atrial fibrillation in these patients. A 56-year-old man was admitted to our hospital for a presyncopal episode. Clinical and instrumental findings led to a diagnosis of light chain cardiac amyloidosis. Hospitalization was complicated by ischemic stroke resulting from embolization of a left atrial thrombus, that occurred in sinus rhythm. This case highlights the importance of a new diagnostic strategy for thromboembolic risk stratification in patients with cardiac amyloidosis. Left atrial strain assessment should be implemented in patients with cardiac amyloidosis to predict the occurrence of thromboembolic events.
Related Concept Videos
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Coronary Artery Disease II: Pathophysiology
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies
Atherosclerosis I: Introduction
Atherosclerosis III: Management

